evipedia.ai
← Back

Ferrous Bisglycinate for Health & Longevity

Evidence Review created on 08/23/2026 using AI4L / Opus 5

Also known as: Iron Bisglycinate, Ferrous Bisglycinate Chelate, Iron Bisglycinate Chelate, Ferrous Bis-Glycinate, Iron(II) Bisglycinate, Ferrochel

Motivation

Ferrous bisglycinate is a form of supplemental iron in which each iron atom is held between two molecules of glycine, one of the smallest amino acids. The idea is that this wrapping shields the iron as it travels through the stomach and small intestine, so less of it reacts with food or irritates the gut lining. Products using it are often sold as gentle iron.

Too little iron is the most common nutritional shortfall in the world, and it is concentrated in menstruating women, endurance athletes, regular blood donors, and people who eat little or no meat. Older iron tablets do raise iron levels, but stomach upset and constipation are common and many people stop taking them. Too much stored iron carries its own hazards, so more is not automatically better.

This review examines the evidence on ferrous bisglycinate: how much it raises iron measures, how its comfort compares with older iron salts, what harms have been recorded, and how it is dosed, timed, and monitored.

Benefits - Risks - Protocol - Conclusion

This section lists high-level expert and academic sources that discuss ferrous bisglycinate, or oral iron repletion more broadly, in substantial depth.

Search note: no directly relevant content was found on hubermanlab.com (only automatically generated clip pages, which are excluded) or on lifespan.io (an on-site search for “iron” returned no article on iron supplementation or iron and aging). Life Extension does publish consumer guides on oral iron, but they are built around the site’s own iron product and never address the bisglycinate chelate. Five qualifying sources were nonetheless identified, so the list is not padded.

Grokipedia

Iron bisglycinate

Covers the chelate’s structure, synthesis, pharmacology, comparisons with other iron forms, clinical evidence, side effects, and economics, including the 2–4 fold absorption advantage claimed over ferrous sulfate.

Examine

No Examine.com article exists for ferrous bisglycinate. Searching the site for “ferrous bisglycinate” or “iron bisglycinate” returns only pages about iron in general, headed by the Iron supplement monograph, which mentions the chelate solely as one entry in its list of iron forms; its supplement coverage of iron is not broken out by chemical form.

ConsumerLab

Iron Supplements Review (Iron Pills, Liquids and Chews)

Independent laboratory testing of marketed iron products, with a Forms of Iron section that compares ferrous bisglycinate against ferrous sulfate, fumarate, gluconate, carbonyl iron, and heme iron polypeptide.

Systematic Reviews

This section lists the systematic reviews and meta-analyses most relevant to the efficacy and the harms of ferrous bisglycinate and of oral iron repletion generally.

Mechanism of Action

Ferrous bisglycinate is a chelate: one ferrous iron ion (Fe²⁺) held by two glycine molecules through both a nitrogen and an oxygen bond, forming two stable five-membered rings. This keeps the iron electrically neutral across the pH swing from stomach acid to the alkaline small intestine, so it resists precipitation and binding by dietary inhibitors such as phytate in grains and legumes, polyphenols in tea and coffee, and calcium.

Two uptake routes are proposed. On the first, the chelate is hydrolysed at the brush border, releasing Fe²⁺ that enters the gut lining cell through the divalent metal transporter DMT1 (the main gateway for non-heme iron). The competing explanation is that part crosses intact through peptide or amino-acid transport. The cell work favours the first: in DMT1-knockout human intestinal cells, uptake from the chelate and from ferrous sulfate was suppressed alike, and the authors concluded DMT1 carries both. Critics add that chelated iron exchanges into the common intestinal iron pool once absorbed, so its edge rests on surviving the gut intact rather than on a separate transporter.

Whichever route dominates, absorbed iron leaves that cell via ferroportin, governed by hepcidin — the liver hormone that shuts ferroportin down when stores are full or inflammation is present. Absorption remains inversely related to serum ferritin, so the body still regulates uptake normally. As a nutrient rather than a drug it has no meaningful half-life, selectivity, tissue distribution, or liver metabolic pathway of its own; the glycine is handled as an ordinary amino acid.

Historical Context & Evolution

Amino acid chelates were developed in the 1960s and 1970s by Albion Laboratories (later Balchem) as a way to deliver minerals in animal feed and fortified foods without the reactivity of inorganic salts. Ferrous bisglycinate was commercialised under the trade name Ferrochel and aimed first at food fortification programmes in Latin America, where sugar, sweet rolls, and milk drinks were fortified for children. Its original purpose was therefore public-health fortification, not individual supplementation.

A conflict of interest runs through the foundational evidence and should be named at the outset: the early safety evaluation and the chemistry characterisation were produced by Albion staff, and the company also sponsored later tolerability trials. That does not invalidate the work, but it means the compound’s favourable early profile was substantially self-reported by its manufacturer.

Interest shifted to health optimisation once independent isotope studies showed superior absorption from inhibitory plant-based meals, and once tolerability emerged as the limiting factor in iron therapy. A structural economic asymmetry also shaped adoption: ferrous sulfate costs a small fraction of the chelate per milligram of elemental iron, so national programmes, insurers, and public formularies have a systematic incentive to favour the cheap salt, and guideline and funding decisions have leaned accordingly. Critiques such as Hallberg and Hulthén’s argued the fortification advantage was overstated; that objection remains on the table rather than settled, and later fortification and supplementation trials have split on it.

Expected Benefits

High 🟩 🟩 🟩

Correction of Iron-Deficiency Anemia

Ferrous bisglycinate raises hemoglobin at least as effectively as conventional iron salts, and in pregnancy somewhat more. A meta-analysis of 17 RCTs found higher hemoglobin in supplemented pregnant women across nine trials, and a Danish RCT showed 25 mg of elemental iron as the chelate matched 50 mg as ferrous sulfate for preventing deficiency through gestation. Evidence in children is neutral rather than favourable, and most trials were conducted in pregnancy or pediatric populations rather than in healthy optimisers.

Magnitude: Standardised mean difference (a pooled effect expressed in units of the spread of the data) 0.54 g/dL (95% confidence interval, or CI — the range in which the true value most likely lies — 0.15 to 0.94) versus comparator iron in pregnancy; 25 mg of chelated iron equalled 50 mg of sulfate iron. See Fischer et al., 2023 and Milman et al., 2014.

Replenishment of Body Iron Stores

Serum ferritin — the iron-storage protein whose blood level tracks total body iron — rises reliably on ferrous bisglycinate. In Mexican schoolchildren with low stores, 30 mg daily for 12 weeks raised ferritin, and the increase was still measurable six months after stopping. Repletion also occurs in adults and in chronic kidney disease. Whether the chelate beats ferrous sulfate on ferritin specifically is unresolved: a Cambodian non-inferiority trial found 18 mg of chelate did not match 60 mg of sulfate.

Magnitude: Ferritin at 12 weeks averaged 84 µg/L on 18 mg of chelate against 99 µg/L on 60 mg of ferrous sulfate and 78 µg/L on placebo in Cambodian women; transferrin saturation rose from 24.7% to 31.3% over 16 weeks in chronic kidney disease. See Duque et al., 2014, Fischer et al., 2023, and Hsu et al., 2022.

Lower Gastrointestinal Adverse-Event Burden Than Conventional Iron Salts

This is the chelate’s strongest differentiating claim. Pooled across randomized trials in pregnancy, reported gastrointestinal (digestive tract) adverse events occurred roughly a third as often as with comparator iron. Two Danish randomized studies comparing equipotent prophylactic doses found ferrous bisglycinate at 25 mg produced the most favourable complaint profile, and black stools in 8% of women versus 22% on fumarate and 31% on sulfate. The mechanism is less unabsorbed reactive iron reaching the colon, helped by the lower elemental dose required — 25–30 mg rather than 100–200 mg.

Magnitude: Incidence rate ratio (IRR — how often an event occurs in one group relative to another over the same period) 0.36 (95% CI 0.17 to 0.76) for gastrointestinal adverse events versus other iron supplements. See Fischer et al., 2023 and Milman & Bergholt, 2024.

Reduction of Fatigue in Iron Deficiency Without Anemia

For the target audience, this is often the operative benefit: low ferritin with normal hemoglobin still produces fatigue, and iron repletion relieves it. A systematic review of RCTs in iron-deficient non-anemic adults found a consistent reduction in self-reported fatigue, replicated in a 2025 meta-analysis of non-anemic children, adolescents, and menstruating adults. The effect disappears when iron-replete participants are included, so the benefit is confined to those who are genuinely depleted.

Magnitude: Standardised mean difference −0.38 (95% CI −0.52 to −0.23) for fatigue across four trials; effect size d = 0.34 for fatigue in the 2025 meta-analysis. See Houston et al., 2018 and Fiani et al., 2025.

Medium 🟩 🟩

Preserved Absorption From Plant-Rich and Inhibitor-Heavy Meals

Phytate in whole grains and legumes cripples absorption of ordinary iron salts. In a stable-isotope study in iron-sufficient men, absorption from ferrous bisglycinate in whole-maize porridge was roughly four times that from ferrous sulfate in the same meal, and the chelated iron did not exchange with the maize iron pool. This matters most for people eating high-phytate, plant-forward diets, and the finding rests on a single controlled human trial.

Magnitude: Geometric mean absorption 6.0% from the chelate versus 1.7% from ferrous sulfate in whole-maize meal. See Bovell-Benjamin et al., 2000.

Improvement of Restless Legs Syndrome Symptoms

Restless legs syndrome (an urge to move the legs, worse at rest and at night) responds to iron repletion, and low brain iron is the leading mechanistic explanation. A meta-analysis of ten randomized trials found a clear symptom-score improvement and a doubled chance of meaningful response. Four of the ten pooled trials used intravenous ferric carboxymaltose rather than oral iron, so the read-across to ferrous bisglycinate is indirect.

Magnitude: International Restless Legs Syndrome score fell by 3.55 points (95% CI −5.41 to −1.68); relative risk (RR — how many times more likely an outcome is) of improvement 2.16. See Avni et al., 2019.

Low 🟩

Exercise Capacity and Aerobic Performance ⚠️ Conflicted

Iron repletion improves aerobic capacity in some but not all trials. A meta-analysis in women of reproductive age found higher maximal oxygen uptake, while a review of non-anemic iron-deficient adults found no objective gain and a 2024 athlete meta-analysis only a trend. Net reading: gains require genuinely depleted stores.

Magnitude: Maximal oxygen uptake +2.35 mL/kg/min (95% CI 0.82 to 3.88) in women of reproductive age; no significant change in non-anemic adults. See Pasricha et al., 2014 and Šmid et al., 2024.

Cognitive Performance and Mood in Iron Deficiency Without Anemia ⚠️ Conflicted

A 2025 meta-analysis reported gains in short-term memory, cognitive test scores, and anxiety, but not attention or depression; the Cochrane review of menstruating women concluded the cognitive evidence was too inconsistent to pool. Net reading: a plausible but unsettled benefit, best treated as secondary to fatigue relief.

Magnitude: Effect sizes d = 0.53 for short-term memory and d = 0.46 for cognitive test scores in randomized trials. See Fiani et al., 2025 and Low et al., 2016.

Speculative 🟨

Favourable Intestinal Redox and Bile-Acid Signalling

In pigs, ferrous bisglycinate lowered intestinal lipid-peroxidation markers and raised glutathione via the AMPK/FOXO pathway (a cellular energy-and-stress signalling route) compared with ferrous sulfate. Basis is animal work only, with no human outcome data.

Support of Iron-Dependent Mitochondrial Enzymes in Later Life

Iron is a cofactor for respiratory-chain enzymes whose activity declines with age, so correcting depletion is proposed to support cellular energy production. Basis is mechanistic reasoning only; no controlled study has tested this endpoint.

Benefit-Modifying Factors

  • Baseline ferritin is the dominant modifier: benefit scales inversely with starting stores. Athlete data show ferritin gains concentrated in those beginning below 12 µg/L, with minimal change above that, and fatigue benefit vanishes once iron-replete participants are included.

  • Iron-status regulation of absorption: fractional absorption from the chelate falls steeply as ferritin rises, so a replete person absorbs a small fraction of what a depleted person absorbs from the identical dose, capping any further benefit.

  • Sex and menstrual status: menstruating women lose iron monthly and show the largest hemoglobin, ferritin, and fatigue responses; men and postmenopausal women without a bleeding source have far less headroom and correspondingly smaller gains.

  • Dietary pattern: the absorption advantage over iron salts is largest in high-phytate, plant-forward diets and shrinks in low-inhibitor meals, so vegetarians, vegans, and heavy whole-grain eaters gain disproportionately from the chelated form.

  • Pre-existing conditions affecting uptake: celiac disease, atrophic gastritis (a thinned stomach lining that makes too little acid), prior bariatric surgery, inflammatory bowel disease (chronic gut inflammation), and chronic inflammation raising hepcidin all blunt oral repletion and may favour intravenous iron.

  • Genetic variation in iron handling: HFE gene variants (the gene regulating iron absorption) such as C282Y and H63D increase uptake and accelerate repletion, while TMPRSS6 variants (the gene controlling hepcidin production) raise hepcidin and slow it, producing markedly different responses at identical doses.

  • Age: older adults absorb iron less efficiently, more often carry inflammation that raises hepcidin, and more often have an occult bleeding source, so a rise in ferritin without a hemoglobin response warrants investigation rather than dose escalation.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Adverse Effects

Nausea, upper abdominal discomfort, constipation, and loose stools are the dominant side effects of all oral iron and are not eliminated by chelation, only reduced. The mechanism is unabsorbed reactive iron irritating the mucosa and altering colonic bacteria. Cochrane data on daily iron in menstruating women show roughly doubled rates of constipation and loose stools versus control. Severity is usually mild and reverses on stopping, and the chelate’s rates run below those of ferrous sulfate rather than at zero.

Magnitude: RR 2.07 (95% CI 1.35 to 3.17) for constipation and RR 2.13 (95% CI 1.10 to 4.11) for loose stools on daily iron; odds ratio (OR — the ratio of the odds of an event between groups) 2.32 for ferrous sulfate versus placebo. See Low et al., 2016 and Tolkien et al., 2015.

Acute Toxicity After Accidental Overdose

Iron is corrosive in bulk and remains a leading cause of serious poisoning in young children, who mistake coated tablets for confectionery. Ingestion causes vomiting, gastrointestinal haemorrhage, metabolic acidosis (blood turning dangerously acidic), and in severe cases hepatic necrosis (death of liver tissue) and shock requiring deferoxamine chelation. A retrospective series identified the threshold for serious toxicity and deferoxamine need in children, while a second series found most unintentional exposures benign. Household storage discipline, not formulation, is the controlling variable.

Magnitude: Serious toxicity threshold approximately 28 mg/kg of elemental iron ingested; symptomatic children had median peak serum iron 66 µmol/L versus 12 µmol/L in asymptomatic children. See Halil et al., 2019 and Crofton et al., 2021.

Medium 🟥 🟥

Iron Accumulation in Genetically Susceptible Individuals

Ferrous bisglycinate delivers absorbable iron, and people who over-absorb it can accumulate stores toward organ-damaging levels. In a UK Biobank cohort of 451,186 adults, men homozygous for the HFE p.C282Y variant — around one in 300 people of northern European descent — carried a sharply elevated risk of primary liver cancer and modestly raised all-cause mortality. Most such carriers are undiagnosed. Reversibility depends on early detection and phlebotomy.

Magnitude: Hazard ratio (HR — the ratio of event rates over time) 10.5 (95% CI 6.6 to 16.7) for hepatic malignancy in male C282Y homozygotes; projected lifetime risk to age 75 of 7.2% versus 0.6%. See Atkins et al., 2020.

Reduced Absorption of Co-Administered Medication

Iron binds levothyroxine, tetracyclines and fluoroquinolones (two families of antibiotics), bisphosphonates (bone-density drugs), levodopa, and methyldopa in the gut lumen, forming poorly soluble complexes. In a clinical trial of 14 people with hypothyroidism taking ferrous sulfate simultaneously with thyroxine, thyroid-stimulating hormone rose and hypothyroid symptoms returned. The chelate delivers the same ferrous iron and is not exempt. The consequence is treatment failure of the other medicine rather than iron toxicity, and it is fully avoidable by separating doses.

Magnitude: Mean thyroid-stimulating hormone rose from 1.6 to 5.4 mU/L over 12 weeks of simultaneous dosing, with symptomatic worsening in 9 of 14 patients. See Campbell et al., 1992.

Black Stools Masking Gastrointestinal Bleeding

Unabsorbed iron darkens the stool, which can be mistaken for, or can conceal, melena (the black tarry stool produced by bleeding higher up the digestive tract) and can confound faecal occult blood screening. Two randomized Danish studies quantified the frequency across equipotent iron forms; the chelate produced the lowest rate, but not a negligible one. The risk is diagnostic rather than physiological, and matters most in older adults being screened for colorectal cancer.

Magnitude: Black stools in 8% of women on 25 mg ferrous bisglycinate versus 22% on 40 mg ferrous fumarate and 31% on 50 mg ferrous sulfate. See Milman & Bergholt, 2024.

Low 🟥

Higher Iron Status and Long-Term Cardiometabolic and Lifespan Signals ⚠️ Conflicted

Mendelian randomization studies — which use inherited variants as a natural experiment — link higher iron status to shorter parental lifespan and raised diabetes risk, yet find iron modestly protective for coronary disease. They describe lifelong genetic tendency, not supplement use. Net reading: replete to sufficiency, not to high-normal stores.

Magnitude: One standard deviation higher genetically predicted serum iron corresponded to 0.70 fewer years of parental lifespan (95% CI −1.17 to −0.24) and OR 0.81 for survival to the 90th percentile age. See Daghlas & Gill, 2021 and Liu et al., 2024.

Iron Supplementation in Infection-Prone Settings

Free luminal and circulating iron feeds bacteria and malaria parasites, and untargeted supplementation of iron-replete children in high-transmission regions has been linked to more infectious illness. The evidence is confounded by baseline iron status and is indirect for replete adults in low-transmission settings, but bears on travel.

Magnitude: Direction of harm is confined to iron-replete children in malaria-endemic areas; the reviewed literature reports no pooled outcome figure for adults. See Iannotti et al., 2006.

Elevated Serum Ferritin Without Corresponding Iron Excess

Ferritin is an acute-phase reactant, so inflammation, infection, alcohol, and metabolic dysfunction raise it independently of iron stores. Dosing against an ordinary reference range can therefore mask true deficiency or create apparent repletion that is inflammatory in origin. The consequence is misdirected dosing rather than toxicity.

Magnitude: Ferritin and low-grade inflammation move together — in 62,537 adults a doubling of plasma ferritin carried an OR of 1.12 (95% CI 1.09 to 1.16) for C-reactive protein at or above 2 mg/L; the literature reports no outcome figure for supplement-driven misclassification. See Moen et al., 2018.

Speculative 🟨

Expansion of Enterobacteriaceae in the Gut Microbiome

In a randomized-trial secondary analysis, ferrous bisglycinate raised the relative abundance of Enterobacteriaceae, a family containing Escherichia coli and Salmonella. Basis is an unvalidated biomarker with no linked clinical outcome.

Ferroptosis and Oxidative Tissue Injury From Chronic Iron Excess

Iron drives ferroptosis, an iron-dependent form of cell death fuelled by lipid peroxidation, which shortens lifespan in nematodes and damages aging retina and brain tissue. Basis is animal and laboratory work only.

Risk-Modifying Factors

  • HFE genotype: C282Y homozygotes and compound heterozygotes over-absorb iron and face materially higher liver-injury and malignancy risk; H63D carriers are affected far less. Genotyping resolves this permanently and is the single highest-yield risk modifier.

  • Baseline ferritin and transferrin saturation: risk is concentrated in the iron-replete. Supplementing above a saturation of about 45% or a ferritin above roughly 150 µg/L moves the profile from repletion toward accumulation with no compensating benefit.

  • Sex: men and postmenopausal women lack monthly iron losses, so identical dosing accumulates stores faster; the liver-cancer signal in C282Y homozygotes was significant in men and not in women.

  • Pre-existing conditions: inflammatory bowel disease, active peptic ulcer, chronic liver disease, fatty liver disease, hemochromatosis (an inherited iron-overload disorder), thalassemia (an inherited defect in making hemoglobin), and repeated transfusion all raise either mucosal-injury or iron-loading risk.

  • Age: older adults more often carry occult gastrointestinal bleeding, polypharmacy that iron can chelate, and inflammation distorting ferritin, so unexplained iron deficiency after roughly age 50 warrants endoscopic evaluation before supplementation continues.

  • Inflammatory state: elevated C-reactive protein (a general inflammation marker) inflates ferritin and raises hepcidin, so iron given during active inflammation is poorly absorbed and more of it remains in the colon.

  • Concurrent medication: proton pump inhibitors (acid-suppressing drugs) reduce absorption of iron salts more than chelated forms, while simultaneous thyroid hormone, antibiotic, or bisphosphonate dosing converts an iron interaction into a therapeutic failure of the other agent.

Key Interactions & Contraindications

  • Levothyroxine (thyroid hormone replacement): caution; simultaneous intake forms an insoluble complex and can cause biochemical and symptomatic hypothyroidism. Separate by at least 4 hours and recheck thyroid-stimulating hormone 6–8 weeks after starting iron.

  • Tetracyclines and fluoroquinolones (doxycycline, minocycline, ciprofloxacin, levofloxacin): caution; iron chelates the antibiotic and can cause treatment failure. Separate iron by 2 hours before or 4–6 hours after the antibiotic dose.

  • Bisphosphonates (alendronate, risedronate — bone-density drugs) and levodopa or methyldopa: caution; reduced absorption of the co-administered drug with loss of therapeutic effect. Take iron at a different time of day from the affected medication.

  • Proton pump inhibitors and H2 blockers (omeprazole, famotidine; both classes reduce stomach acid): monitor; raising gastric pH impairs solubilisation of ionic iron. Ferrous bisglycinate is less pH-dependent, so it is the more logical choice for people on chronic acid suppression.

  • Mycophenolate, penicillamine, and integrase inhibitors (dolutegravir, raltegravir — HIV medicines): caution; iron markedly reduces plasma levels of each. Separate dosing by at least 2 hours before or 6 hours after, and confirm with the prescriber.

  • Calcium and zinc supplements: monitor; divalent cations compete for shared intestinal transport and reduce iron uptake. Take calcium and zinc at a separate meal from the iron dose.

  • Vitamin C (ascorbic acid): additive; 100–250 mg taken with the dose enhances iron absorption. The additive effect is desired but means an unchanged tablet dose can deliver more iron than expected.

  • Lactoferrin, heme iron polypeptide, and multivitamins containing iron: additive; stacking iron sources produces unintended cumulative elemental iron. Total daily elemental iron from all products should be counted, not just the dedicated supplement.

  • Deferoxamine, deferasirox, and other iron chelators: absolute contraindication when taken together; iron supplementation directly opposes chelation therapy for iron overload.

  • Blood donation and therapeutic phlebotomy: caution, and an absolute contraindication where phlebotomy treats iron overload; each unit removes roughly 200–250 mg of iron, so donors have a genuine repletion need while iron-overload phlebotomy is negated by supplementation.

Populations who should avoid Ferrous Bisglycinate:

  • Hereditary hemochromatosis, including HFE C282Y homozygotes and compound heterozygotes, whether or not iron indices are currently normal
  • Transfusion-dependent thalassemia, sideroblastic anemia (failure to build hemoglobin despite ample iron), and myelodysplastic syndrome (a bone-marrow failure disorder) with transfusional iron loading
  • Anyone with transferrin saturation above 45% or ferritin above 300 µg/L in men or 200 µg/L in women without documented iron deficiency
  • Porphyria cutanea tarda and erythropoietic protoporphyria (rare inherited faults in heme production that cause blistering and light-sensitive skin), in which iron loading aggravates the disease
  • Active untreated peptic ulcer disease or an unevaluated gastrointestinal bleed
  • Anemia not established as iron-deficient — including anemia of chronic disease and vitamin B12 or folate deficiency
  • Households with children under 6 years where child-resistant storage cannot be guaranteed

Risk Mitigation Strategies

  • Test before treating: confirm ferritin below roughly 30 µg/L or transferrin saturation below 20% before starting, which prevents the accumulation, diabetes, and lifespan risks that attach specifically to supplementing the iron-replete.

  • Genotype once for HFE: a single C282Y and H63D test permanently excludes the highest-consequence risk, the tenfold liver-malignancy signal in male homozygotes, and costs nothing thereafter.

  • Use the lowest effective elemental dose: 25–30 mg daily achieves repletion in most adults; lower unabsorbed colonic iron is the direct mechanism behind fewer digestive complaints and less microbiome disturbance.

  • Dose on alternate days: morning doses every second day lower hepcidin between doses, cutting gastrointestinal complaints roughly a third while matching daily dosing on iron stores.

  • Separate from interacting medication: take iron at least 4 hours from levothyroxine and 2 hours from antibiotics, bisphosphonates, and levodopa, which prevents therapeutic failure of the co-administered drug.

  • Stop at target and retest: recheck ferritin and transferrin saturation at 8–12 weeks and discontinue once ferritin reaches 50–100 µg/L, preventing silent accumulation toward organ-loading levels.

  • Investigate unexplained deficiency before continuing: in men and in anyone over 50, evaluate for occult gastrointestinal bleeding rather than supplementing indefinitely, since iron masks the anemia without addressing the cause.

  • Store in child-resistant packaging out of reach: unintentional pediatric ingestion produces serious toxicity above roughly 28 mg/kg of elemental iron, and packaging discipline is the only effective control.

Therapeutic Protocol

  • Standard repletion dose: 25–30 mg of elemental iron as ferrous bisglycinate is the dose used by clinicians favouring chelated iron, and matched 50 mg of ferrous sulfate for prophylaxis in a randomized pregnancy trial.

  • Alternate-day scheduling: the ETH Zurich group of Stoffel, Moretti, and Zimmermann popularised morning dosing every second day; a randomized trial showed equal ferritin, fewer complaints, and less deficiency at six months.

  • Competing conventional approach: hematology guidelines still commonly specify 100–200 mg of elemental iron daily as ferrous sulfate in divided doses, and a 2025 meta-analysis found daily and alternate-day schedules comparably effective.

  • Best time of day: morning, on an empty stomach or 1 hour before food. Hepcidin follows a circadian rise through the day, so an afternoon or evening dose is absorbed less efficiently.

  • Single versus split dosing: single doses are preferred. Splitting 120 mg into two daily doses raised hepcidin without increasing total absorption in a randomized crossover trial.

  • Half-life: ferrous bisglycinate is a nutrient with no meaningful elimination half-life; the operative kinetic is the roughly 24-hour hepcidin surge following a dose, which is why alternate-day timing works.

  • Vitamin C co-administration: 100–250 mg of ascorbic acid with the dose is standard practice; the chelate is less dependent on it than iron salts because it resists dietary inhibitors already.

  • Genetic influences on dose: HFE C282Y and H63D carriers absorb more and need less, while TMPRSS6 variants raise hepcidin and blunt response; the genes for Alzheimer’s risk (APOE4), folate processing (MTHFR), and dopamine breakdown (COMT) are not relevant here.

  • Sex-based differences: menstruating women commonly need continuous cyclical repletion; men and postmenopausal women generally need a defined course to a ferritin target and then cessation.

  • Age-related considerations: older adults absorb less and inflame more, so a longer course at the same low dose is preferable to escalation, with occult bleeding excluded first.

  • Baseline biomarkers guiding dose: ferritin below 15 µg/L with anemia warrants the full 25–30 mg course; ferritin of 30–50 µg/L without anemia warrants a shorter or intermittent course.

  • Conditions influencing response: celiac disease, atrophic gastritis, prior bariatric surgery, chronic kidney disease, and inflammatory bowel disease all blunt oral response and may indicate intravenous iron instead.

Discontinuation & Cycling

  • Course length, not lifelong use: ferrous bisglycinate is a corrective course, typically 8–12 weeks to normalise hemoglobin and 3–6 months to rebuild stores, rather than an indefinite daily supplement.

  • No withdrawal effects: stopping produces no rebound or withdrawal syndrome. Stores simply decline again at the rate of ongoing losses, which is roughly 1–2 mg daily plus menstrual loss.

  • No taper required: the compound can be stopped abruptly. Any taper is a matter of dose-finding toward maintenance, not of physiological dependence.

  • Cycling is the norm for ongoing losses: menstruating women, frequent donors, and endurance athletes commonly cycle — repletion courses interspersed with retesting — rather than dosing continuously, which prevents accumulation.

  • Intermittent maintenance: where losses persist, one to three doses weekly maintains ferritin without the accumulation risk of daily use, and alternate-day data support intermittent efficacy.

  • Stopping trigger: discontinuation is indicated once ferritin reaches roughly 50–100 µg/L or transferrin saturation exceeds 45%, whichever comes first, since further dosing adds risk without benefit.

Sourcing and Quality

  • Verify the chelate, not just the word iron: labels should specify ferrous bisglycinate chelate and state elemental iron separately from compound weight; 25 mg of elemental iron corresponds to roughly 125 mg of the chelate.

  • Look for the Ferrochel or TRAACS designation: these identify Balchem’s patented chelate used in most published trials, which provides traceability to the specific material studied rather than a generic equivalent.

  • Third-party testing: prefer products carrying NSF, USP Verified, or Informed Choice certification, which confirms the stated elemental iron content and screens for heavy-metal contamination in the mineral raw material.

  • Beware blended and hidden iron: prenatal formulas, greens powders, and multivitamins frequently contain additional iron; total elemental iron across all products should be tallied before adding a dedicated supplement.

  • Formulation choice: capsules and tablets are preferable to liquids for anyone concerned about dental staining; liquid chelate is useful where swallowing is difficult but should be taken through a straw.

  • Reputable manufacturers: Thorne, Pure Encapsulations, Solgar, and Designs for Health market ferrous bisglycinate products with published certificates of analysis; compounding pharmacies are not required for this compound.

Practical Considerations

  • Time to effect: young red blood cells rise within 7–10 days and hemoglobin within 3–4 weeks, but ferritin and symptom relief typically take 8–12 weeks, and full store repletion 3–6 months.

  • Common pitfall — dosing too high: exceeding 60 mg of elemental iron triggers a sustained hepcidin rise that suppresses absorption from the next dose while leaving more iron in the colon to cause symptoms.

  • Common pitfall — taking it with coffee or tea: polyphenols still reduce absorption even from the chelate; the dose belongs at least an hour away from tea, coffee, dairy, and calcium supplements.

  • Common pitfall — treating without testing: dosing on symptoms alone risks supplementing the already replete, which carries accumulation and metabolic risk with no offsetting benefit.

  • Common pitfall — stopping when hemoglobin normalises: hemoglobin recovers well before stores do, and stopping at that point predictably leads to relapse within months.

  • Regulatory status: ferrous bisglycinate is a dietary supplement ingredient in the United States and an authorised source of iron in food supplements in the European Union; it is not a prescription medicine.

  • Cost and accessibility: widely available without prescription, though several times the price of ferrous sulfate per milligram of elemental iron — a gap that also shapes which form public programmes and formularies adopt.

Interaction with Foundational Habits

  • Sleep: indirect and generally favourable. Correcting iron deficiency relieves restless legs syndrome and periodic limb movements, which fragment sleep; the meta-analytic symptom improvement is the mechanism. Iron itself is neither sedating nor stimulating, so morning dosing costs nothing in sleep terms and fits the hepcidin rhythm.

  • Nutrition: direct and bidirectional. Phytate, polyphenols, calcium, and zinc blunt absorption, while ascorbic acid and meat protein enhance it; the chelate resists inhibition better than iron salts but is not immune. Best taken away from meals, or with a vitamin C source if an empty stomach is not tolerated.

  • Exercise: direct and potentiating in the deficient. Endurance training raises iron losses through sweat, red-cell breakdown, and exercise-induced hepcidin elevation, so athletes deplete faster. Dosing at least 30 minutes before or several hours after hard training avoids the post-exercise hepcidin peak that suppresses absorption.

  • Stress management: indirect. Chronic stress and inflammation raise hepcidin and interleukin-6, which both suppress iron absorption and inflate ferritin, so a stressed or inflamed state makes oral iron less effective and its monitoring less reliable. Measuring C-reactive protein alongside ferritin resolves the ambiguity.

Monitoring Protocol & Defining Success

Before starting, iron deficiency should be documented rather than assumed. A baseline panel comprising a complete blood count, ferritin, transferrin saturation, serum iron with total iron-binding capacity, and high-sensitivity C-reactive protein establishes both the deficit and whether inflammation is distorting ferritin. A one-time HFE genotype removes the largest single safety uncertainty. Ongoing monitoring follows a defined cadence: repeat ferritin and a complete blood count at 8 weeks, again at 12 weeks, and then every 3–6 months while supplementation continues, dropping to every 6–12 months once a maintenance schedule is established. Success is defined as ferritin in the 50–100 µg/L band with transferrin saturation of 25–35%, normal hemoglobin, and resolution of fatigue — not by the highest ferritin achievable.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Ferritin 50–100 ng/mL (women); 50–150 ng/mL (men) Best single index of total body iron stores Conventional range starts at 15 ng/mL, far below the functional target; rises with inflammation, so pair with high-sensitivity C-reactive protein. No fasting needed
Transferrin saturation 25–35% Iron available for delivery to tissues; the earliest overload signal Conventional range 20–50%; above 45% suggests accumulation and argues for stopping. Draw fasting in the morning, as values swing widely through the day
Hemoglobin 13.0–15.0 g/dL (women); 14.0–16.0 g/dL (men) Confirms whether deficiency has progressed to anemia and tracks response Recovers well before stores do, so it must not be the stopping criterion. Part of the complete blood count
MCV and RDW MCV 85–92 fL; RDW below 13% Early morphological signature of iron deficiency; RDW rises before MCV falls MCV is mean corpuscular volume, the average red cell size; RDW is red cell distribution width, the variation in red cell size. Conventional ranges are far wider — MCV 80–100 fL and RDW below 15% — so a result inside them can still mark early depletion. Included in the complete blood count at no extra cost; a high MCV alongside low iron suggests concurrent vitamin B12 or folate deficiency
Soluble transferrin receptor Within the assay’s stated reference interval, toward the lower half Reflects tissue iron demand and, unlike ferritin, is not raised by inflammation The tie-breaker when ferritin and C-reactive protein are both elevated. Assay-specific, so use the reporting laboratory’s own interval
High-sensitivity C-reactive protein Below 1.0 mg/L Determines whether a ferritin value is trustworthy Above 5 mg/L, ferritin should be interpreted as inflated and repeated after the inflammatory episode resolves
ALT Below 25 U/L (men); below 20 U/L (women) Detects hepatic injury from iron accumulation ALT is alanine aminotransferase, a liver enzyme. Conventional upper limits near 40–50 U/L are considerably more permissive than the functional target. Most relevant in HFE carriers and long-term users
HbA1c Below 5.4% Iron loading impairs pancreatic beta-cell function, so this tracks the metabolic consequence of excess HbA1c is glycated hemoglobin, a measure of average blood sugar over about three months. The conventional cut-off is below 5.7%, a more permissive threshold than the functional target. Falsely low when red cell turnover is high during active iron repletion; interpret alongside fasting glucose
HFE genotype (C282Y and H63D) No numeric range applies; the result is a genotype. Track the paired transferrin saturation trend instead Identifies the small group at high risk of iron loading before any supplementation begins One-time test, no fasting. A C282Y homozygous result is a reason not to supplement rather than a value to optimise

Qualitative markers worth tracking alongside the laboratory panel:

  • Daytime fatigue and exercise recovery, ideally scored weekly on a consistent scale rather than recalled
  • Cold intolerance, particularly in the hands and feet
  • Restless legs symptoms and the number of night-time awakenings
  • Cognitive clarity and short-term memory during demanding work
  • Exercise capacity at a fixed workload, such as heart rate at a habitual pace
  • Hair shedding, brittle nails, and paleness of the inner eyelid
  • Pica (craving non-food substances such as ice or clay), a specific and often-missed sign of iron deficiency
  • Gastrointestinal comfort and stool consistency on the current dose and schedule

Emerging Research

  • EASE-Iron head-to-head trial: NCT06014983 randomises 172 pregnant participants in Vancouver to ferrous bisglycinate or ferrous fumarate, with maternal ferritin as the primary endpoint and gut microbiome composition as a secondary. Recruiting, primary completion December 2026.

  • Dosing-frequency trials in pregnancy: NCT07657455 compares daily against alternate-day oral iron in 184 second-trimester pregnancies, measuring hemoglobin change, adherence, and digestive side effects — the design most likely to settle whether the alternate-day advantage generalises.

  • Iron status and biological aging: Guo et al., 2023 reported that genetically higher ferritin and transferrin saturation accelerate all four major epigenetic clocks. If replicated, this would sharpen the case for capping repletion rather than maximising stores.

  • Iron status and dementia risk: Casanova et al., 2024 found higher genetically predicted transferrin saturation raised non-Alzheimer’s and vascular dementia risk in 451,284 UK Biobank participants, independently of APOE ε4 (the main genetic risk variant for Alzheimer’s disease).

  • Competing delivery technologies: Secrest et al., 2025 reported that glycoprotein matrix-bound iron outperformed ferrous bisglycinate chelate and ferrous fumarate on absorption in a randomized crossover trial — evidence that would weaken, not strengthen, the case for the chelate.

  • Microbiome consequences of iron form: Finlayson-Trick et al., 2023 found ferrous bisglycinate raised Enterobacteriaceae abundance relative to placebo. Whether this translates into clinical harm is the open question, and larger stool-endpoint trials are needed.

  • Ferritin-guided supplementation in donors: the FORTE trial, Karregat et al., 2025, tested ferritin-guided iron against extended donation intervals in blood donors, a directly relevant model for optimisers with recurrent iron losses.

  • Impact of dosing regimens on iron biomarkers: the PANDA trial, Haynes et al., 2026, reports how oral iron dosing regimens shift hepcidin and iron biomarkers across pregnancy, extending the alternate-day question into a population with high iron demand.

Conclusion

Ferrous bisglycinate is iron wrapped in two molecules of a common amino acid, a design intended to let the mineral pass through the gut without reacting with food or irritating the lining. On its central claim the evidence holds up: it raises blood iron and stored iron at least as well as older iron salts, and it does so at roughly half the iron dose while producing markedly fewer digestive complaints. For people who abandoned conventional iron because of nausea or constipation, that difference is the whole point.

The evidence base is uneven. It is strongest in pregnancy, thinner in men and non-pregnant women, and much of the foundational safety and chemistry work was produced or funded by the company that patented the compound — a conflict that leaves its early advantages less independently established than they first appear. Cost also shapes the field, since the cheaper conventional salt has structural advantages in public programmes and in the approved purchasing lists health systems buy from, for reasons unrelated to the biology.

The pattern running through the evidence is one of restraint. Benefit is confined to those who are genuinely depleted, and genetic and population evidence links higher lifelong iron status to shorter life expectancy, higher diabetes risk, and faster measures of biological aging. The trials with the cleanest results are those that confirmed depletion first, used the smallest dose that worked, spaced doses every second day, and stopped once stores were comfortably filled.

Top - Benefits - Risks - Protocol